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DAILY UNM GLOBAL HEALTH COVID-19 BRIEFING
June 3-4, 2020

Executive Summary
NM Highlights: Navajo Nation to end weekend curfew. NM case count. Navajo Nation case updates. Food
distribution by PepsiCo. APS to get funding.
US Highlights: 5 vaccine candidates. Arizona’s increased cases. Some states postpone primaries. Pork plant
infections.
Economics, Workforce, Supply Chain, PPE: Impact on global supply chains. Residency selection process
disrupted. Facemask filtration efficiency. Resources for underserved countries.
Epidemiology Highlights: Morbidity and mortality in Africa.
Healthcare Policy Recommendations: Need for social distancing. Psychological support guide. Return to
work guidelines.
Practice Guidelines: Anesthesia recommendations for ECT. Extracorporeal membrane oxygenation outcomes.
Testing: Roche Elecsys IL-6 test is authorized by FDA to identify severe inflammatory response.
Drugs, Vaccines, Therapies, Clinical Trials: HCQ RCT does not show disease prevention. Lancet HCQ study
retraction. Adjunctive convalescent plasma did not show clinical improvement. Mixed remdesivir results.
Virtual drug screening. Heparin improved survival. Moderna phase 3. Skin science for vaccine development.
ECMO therapy. 48 new clinical trials.
Other Science: Androgens and poor male outcomes. Trust in science enhances prevention compliance. High
VTE prevalence in critically ill.
All of our past briefings are maintained in a UNM library repository here.
Our continuously curated practice guidelines in the context of COVID-19 can be found here.
Our continuously curated therapeutic evidence is maintained here.
You may submit content for future briefings here.

NM Highlights


Navajo Nation to end 57-hour weekend curfew and lockdown
While the weekend curfew and lockdown will end, the 7-day nightly curfew will continue. The nightly curfew is from 8 p.m. 5 a.m. The Navajo Nation has reported 5,533 COVID-19 cases and 248 deaths.



NM reports 8 more COVID-19 deaths and 218 additional cases on June 4
As of today (6/4), the total positive cases and total deaths in the state are 8,353 and 383, respectively. The state has
performed 217,757 tests, there are 170 individuals currently hospitalized for COVID-19, and 3,115 COVID-19 cases have

recovered. NMDOH portal featuring epidemiologic breakdown of cases.



Navajo Nation reports 54 new cases of COVID-19 and 4 additional deaths on June 2
The Navajo Department of Health reported 54 new cases of COVID-19 and four additional deaths Tuesday. The total number
of confirmed COVID-19 cases for the Navajo Nation has reached 5,533 with 248 deaths.



PespiCo’s Food for Good delivered 94,000 meals to tribal communities
Food for Good, a nutrition program by PepsiCo, distributed more than 94,000 meals to Pueblo communities over the last
several weeks. This is all part of a $60 million initiative to feed at-risk communities during the COVID-19 pandemic.



APS anticipating $26M from CARES Act
Albuquerque Public Schools is expecting nearly $26 million in Coronavirus Aid, Relief and Economic Security Act funds to help
pay for device and internet costs, personal protective equipment, and cleaning supplies for classrooms and buses.

US Highlights


Trump administration selects five COVID vaccine candidates to begin testing in late July
NY Times: The companies are: Moderna Inc, AstraZeneca Plc, Pfizer Inc, Johnson and Johnson, Merck and Co Inc. A vaccine is
expected by the end of the year with millions of doses by 2021.



Arizona’s highest single-day rise in cases - state experts blame ending lockdown
Newsweek: The state reported 1,127 new infections of the novel virus, the highest number reported in a single day since the
outbreak began, according to the dashboard updated by the Arizona Department of Health Services. The state also reached a
new record of more than 1,000 hospitalizations due to COVID-19 on Monday, suggesting the state is seeing an increase in
more serious infections likely due to not following the CDC guidelines.



4 states held primaries this week and 5 postponed
USA Today: There are multiple presidential primary elections taking place around the country Tuesday as election season
chugs forward amid the coronavirus pandemic. NM. SD, DC, MT held primaries, IN, MD, PA & RI postponed.



Tyson Foods: 591 workers at Storm Lake pork plant test positive for COVID-19
Sioux City Journal: That's a quarter of the 2,303 workers who work at the facility and were tested for COVID-19. The vast
majority of the plant's workers reside in Buena Vista County, which had 854 total cases of the virus with its first COVID-19related death. If all the workers who tested positive lived in Buena Vista County, they would account for roughly 70 percent
of the Northwest Iowa county's total cases.

Economics, Workforce, Supply Chain, PPE Highlights


Duration of lockdown and spatial extent has great impact on global supply chains
Nature: The authors modelled four different sets of pandemic scenarios, three of which (36 scenarios in total) represent
different spread extents and containment responses to the COVID-19 pandemic. The spatial extent of the pandemic is the
most important driver of the global cost. It was found that the global supply-chain effects increase almost fourfold to 12.6%.
The modeled impacts of global lockdowns in response to COVID-19 are greater still—26.8% of global GDP. The second insight
from the model is the importance of propagation through global supply chains—even countries that are not directly affected
by the virus experience large losses, and low- and middle-income countries are more vulnerable to indirect effects.



COVID-19 disrupts residency selection process, test centers close
JAMA: Disruptions caused by COVID-19 may result in an increased number of applications this year. In 2019-2020, applicants
from US medical schools applied to an average of 65 programs, and international medical graduates (IMGs) applied to an
average of 137 programs. Due to testing center closures, many applicants are unable to take portions of the US Medical
Licensing Examination (USMLE). This is especially critical for IMGs who must pass the Step 2 Clinical Skills Examination to
obtain certification from the Educational Commission for Foreign Medical Graduates and apply to US residency programs.
Medical schools shortened clerkships shifted to virtual rotations and canceled away electives. Conducting virtual interviews

or waiving requirements for USMLE scores and letters of recommendation, will be necessary. The other recommendations
include emphasis on narrative aspects of the application, encouraging students to focus NOT on quantity but quality of their
applications, and capping the number of interviews a student can accept.



Household materials selection for homemade cloth face coverings
Nano Letters: The authors evaluated the filtration properties of natural and synthetic materials using a modified procedure
for N95 respirator approval. Cotton, polyester, nylon, and silk had filtration efficiency of 5-25%, polypropylene spunbond had
filtration efficiency 6-10%, and paper-based products had filtration efficiency of 10-20%. An advantage of polypropylene
spunbond is that it can be simply triboelectrically charged to enhance the filtration efficiency (from 6 to >10%), without any
increase in pressure (stable overnight and in humid environments). Cotton, polyester, and polypropylene multilayered
structures can meet or even exceed the efficiency of materials used in some medical face masks.



Vaccine group plans agreement to secure resources for underserved countries
Reuters: GAVI vaccines agree to launch Advance Market Commitment (AMC) for future vaccines to secure resources. GAVI, a
public-private partnership backed by the Bill & Melinda Gates Foundation, WHO, the World Bank, UNICEF and others,
arranges bulk buys to reduce vaccine costs for poor countries. This AMC is an incentive for manufactures to invest in trial and
production as well as prevent wealthier countries from buying all future vaccines.

Epidemiology Highlights


Morbidity and mortality of COVID-19 in Africa
Am J Tropical Med Hygiene: There is lower morbidity and mortality due to COVID-19 in Africa than globally. This review
examined the merits of various hypotheses advanced to explain this phenomenon, including low seeding rate, effective
mitigation measures, a youthful population, favorable weather, and possible prior exposure to a cross-reactive virus. Having a
youthful population and favorable weather appears compelling, particularly the combined effect. However, progression of
the pandemic in the region and globally may dispel these hypotheses in the coming months.

Healthcare Policy Recommendations


Ongoing need for social distancing and control measures after a "lockdown"
European Respiratory Journal: Most countries with significant outbreaks have introduced social distancing or "lockdown"
measures to reduce viral transmission but the key question is when, how, and to what extent these measures can be lifted.
Data on daily numbers of newly confirmed cases and mortality were used to fit regression models estimating trajectories,
doubling times and the reproduction number (R0) of the disease before and under the control measures. The estimates of R0
before lockdown (2.0 - 3.7 for USA, Italy, Spain, France and UK) were broadly consistent with those previously published.
There was little evidence to suggest that the restrictions had reduced R far below 1 in many places. The data are more
consistent with a need to adopt a “new normal” that can provide the optimal balance between allowing economic activity
while ensuring very substantial reductions (at least 80%) in prior social contacts.



Guide to psychological support for healthcare workers
Inter-Agency Standing Committee: The Inter-Agency Standing Committee released a "Basic Psychosocial Skills: Guide for
COVID-19 Responders" to aid in self-care, supportive communication for others, offering practical support, supporting those
who are in emotional distress, and resources for law enforcement, refugee situation, those grieving, etc. It highlights the
importance of personal wellness in order to be able to care for others. There are sample cases for various scenarios and ways
to help, as well as meditation techniques.



Return to work guidelines for the COVID-19 pandemic
Occupational Medicine: A panel of experts was convened by the Spanish Association of Occupational Medicine (AEEMT) to
elaborate return to work guidelines for high-risk workers, low-risk workers, and for direct COVID-10 contacts. Practical
schemas are suggested.

Practice Guidelines


General anesthesia recommendations for ECT during the COVID-19 pandemic
The Journal of ECT: The Weill Cornell Medicine- New York Presbyterian Hospital Anesthesiology and Psychiatry departments
collaborated to develop guidelines for electroconvulsive therapy anesthesia during COVID-19 pandemic

Testing


Roche inflammatory response test receives FDA emergency use approval for COVID-19 patients
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has issued an
Emergency Use Authorization (EUA) for the Elecsys® IL-6 test. This test measures levels of the biomarker interleukin 6 (IL-6)
and can be used to help identify patients with confirmed COVID-19 disease who could be at high risk of intubation with
mechanical ventilation. Hospitals and reference laboratories can run the test on Roche’s cobas e® analysers which are widely
available around the world. These fully-automated systems can provide test results in approximately 18 minutes, with a test
throughput of up to 300 tests/hour, depending on the analyser.



Clearance and Persistence of SARS-CoV-2 RNA in COVID-19 patients
Journal of Medical Virology: SARS‐CoV‐2 viral clearance profile is crucial to establish a re‐testing plan on discharge and ending
isolation of patients. This study aimed to evaluate the number of days patients needed to achieve undetectable levels of
SARS‐CoV‐2 in upper respiratory tract specimens. Patients were grouped by management of illness (treated in home vs. in
hospital) and also by whether they achieved two negative test results or had continued positive tests within the study
timeframe. Patients’ RT‐PCR results were also correlated with their immune response testing results. The study found that
most patients tested positive for more than two weeks and that persistence of viral RNA is not necessarily associated with
severe disease but may result from a weaker immune response instead.

Drugs, Vaccines, Therapies, Clinical Trials


Hydroxychloroquine did not prevent illness compatible with COVID-19 in a double-blind RCT
NEJM: A randomized, double-blind, placebo-controlled trial tested HCQ as postexposure prophylaxis. They enrolled adults
with a high- or moderate-risk exposure to SARSCoV2. Within 4 days after exposure, the authors randomly assigned
participants to receive either placebo or HCQ (N=821 asymptomatic participants). 87.6% reported a high-risk exposure to a
confirmed Covid-19 contact. The incidence of new illness compatible with Covid-19 did not differ significantly between
participants receiving HCQ (11.8% and those receiving placebo 14.3%; the absolute difference was −2.4 percentage points
(95% confidence interval, −7.0 to 2.2; P=0.35). Side effects were more common with HCQ than with placebo (40.1% vs.
16.8%), but no serious adverse reactions were reported.



Study authors retract Lancet article suggesting no benefit of hydroxychloroquine for COVID-19 patients
The Lancet: Following expressions of concern, authors retracted an influential article on hydroxychloroquine originally
published on May 22. The original article found there was no benefit of treatment with chloroquine or hydroxychloroquine in
hospitalized COVID-19 patients and raised concerns regarding the risk/benefit ratio of these therapies outside of the
treatment of autoimmune diseases. However, the authors were not able to obtain an independent audit of the data
underpinning these conclusions, and the Lancet published their retraction of the article on June 4.
Here is the official retraction.



Adjunctive convalescent plasma did not result in a shorter time to clinical improvement
JAMA: Open-label, multicenter, randomized clinical trial included 103 participants with severe/life-threatening COVID-19 was
terminated early after 103 of a planned 200 patients were enrolled. Clinical improvement within 28 days was not significantly
improved for the convalscent plasma group (51.9% 27/52) compared to the control group (43.1% 22/51) (difference, 8.8%
[95% CI, −10.4% to 28.0%]; hazard ratio [HR], 1.40 [95% CI, 0.79-2.49]; P = .26). There was no significant difference in 28-day
mortality (15.7% vs 24.0%; OR, 0.65 [95% CI, 0.29-1.46]; P = .30) or time from randomization to discharge (51.0% vs 36.0%
discharged by day 28; HR, 1.61 [95% CI, 0.88-2.93]; P = .12). Convalescent plasma treatment was associated with a negative

conversion rate of viral PCR at 72 hours in 87.2% of the convalescent plasma group vs 37.5% of the control group (OR, 11.39
[95% CI, 3.91-33.18]; P < .001).



Remdesivir results mixed in moderate COVID-19 patients
Reuters: A late-stage safety and efficacy trial of remdesivir in 600 patients with moderate COVID-19 found that 76% of
patients treated for 5 days and 70% of patients treated for 10 days achieved clinical improvement compared to only 66% of
patients given standard care. While the 5-day treatment group did achieve a significant increase in the percentage of patients
who were improved, the percentage of patients who were clinically improved in the 10-day treatment group did not achieve
significance. These findings indicate that remdesivir has some utility in treatment of moderate COVID-19 patients, but
benefits are likely modest and protocols need to be clarified.



Virtual screening-driven drug discovery of SARS-CoV2 enzyme inhibitors
Journal of Biomolecular Structure and Dynamics: With the aid of bioinformatics and computational modelling, 97 antiviral
secondary metabolites from fungi were docked onto five SARS-CoV2 enzymes involved in viral attachment, replication, posttranslational modification, and host immunity evasion infection mechanisms followed by molecular dynamics simulation and
in silico ADMET prediction (absorption, distribution, metabolism, excretion and toxicity) of the hit compounds. Thus, three
fumiquinazoline alkaloids scedapin C (15), quinadoline B (19) and norquinadoline A (20), the polyketide isochaetochromin D1
(8), and the terpenoid 11a-dehydroxyisoterreulactone A (11) exhibited high binding affinities on the target proteins, papainlike protease (PLpro), chymotrypsin-like protease (3CLpro), RNA-directed RNA polymerase (RdRp), non-structural protein 15
(nsp15), and the spike binding domain to GRP78. Of the five top-scoring metabolites, quinadoline B (19) was predicted to
confer favorable ADMET values, high gastrointestinal absorptive probability and poor blood-brain barrier crossing capacities.



Search for natural inhibitors of SARS-CoV2 protease by molecular docking and simulation
Journal of Biomolecular Structure and Dynamics: The authors performed in silico screening of compounds from Curcuma
longa L. against Mpro protein inhibition. Employing a combination of molecular docking, scoring functions, and molecular
dynamics simulations, 267 compounds were screened by docking on Mpro crystallographic structure. X-ray crystallographic
structure of the SARS-CoV2 Mpro protein demonstrated the significance of Glu166, Cys141, and His41 residues involved in
protein dimerization and its catalytic function.



The association between treatment with heparin and survival in patients with Covid-19
Journal of Thrombosis and Thrombolysis: In a prospective study, clinical data were collected from the 2075 patients with
Covid-19, admitted in 17 hospitals in Spain. Heparin had been used in 1734 patients and was associated with lower mortality
when the model was adjusted for age and gender, with OR (95% CI) 0.55 (0.37-0.82) p = 0.003. This association remained
significant when saturation of oxygen < 90%, and temperature > 37 degrees C were added to de model with OR 0.54 (0.360.82) p = 0.003, and also when all the other drugs were included as covariates OR 0.42 (0.26-0.66) p < 0.001.



Moderna phase 3 trial will begin in July
Forbes: The phase 3 trial of Moderna’s experimental vaccine for COVID-19 will begin in July with 30,000 patients. A phase 3
trial follows testing for safety, and is designed as a randomized controlled trial to establish benefit of the vaccine over
placebo. The trial will include primarily US sites but also international sites, and is the final step before potential approval by
the FDA for general use.



Advances in skin science may enable development of COVID-19 vaccine
Journal of the American Academy of Dermatology: A commentary and review showed the potential of cutaneous delivery
strategies for vaccines and immune-modulation therapies via biotechnology such as microneedle arrays. These approaches
may allow for the development of novel vaccine strategies and immunotherapies, as well as negative immunization strategies
for immune regulation in the treatment of systemic allergy and autoimmune diseases.



Extracorporeal membrane oxygenation for respiratory failure in COVID-19 patients
Canadian Journal of Anesthesia: In a prospective case series study the data were collected on 12 COVID-19 patients admitted
for ECMO therapy continuing for 12 days. 67% of patients were discharged from the ICU and 33% died. All patients were
treated with inhaled nitric oxide, neuromuscular blockade, and prone positioning prior to ECMO therapy. All patients
received heparin treatment. Common complications of disease in ECMO patients included acute kidney injury (92%),

thrombosis (92%), and ventilator associated pneumonia (83%). For patients weaned from ECMO, biological data showed an
increase in lymphocyte count (from 560 mm-3 to 1,280 mm-3) and a decrease in fibrinogen (from 6.8 gL-1to 3.6 gL-1). There
was an increase in PaO2/FIO2 ratio from 129 mmHg to 268 mmHg, and an initial decrease in respiratory compliance from
29.3 to19.3 mLmmHg-1, followed by an increase to 26.8 mLmmHg-1.



48 new clinical trials for COVID-19 therapies registered over the course of 2 days
Clinicaltrials.gov: 48 new trials of therapies for COVID-19 were registered at clinicaltrials.gov between June 3 and June 4. The
drugs to be studied include Colchine, Hydroxychloroquine, Dexmedetomidine, Ruxolitinib, Nivolumab, Tofacitinib, Conestat
Alfa, Mesenchymal Stem Cell, LAU-7b, KB109, Opaganib, Bacillus Calmette-guerin, Axatilimab. At time of writing, a total of
1841 clinical trials were active, 119 completed, and 4 posted results.

Other Science


Androgens may explain why men have worse COVID-19 outcomes than women
Science. Data from around the world show that men have a greater risk of severe illness and death from COVID-19 than
women. More data are now generated supporting the hypothesis that androgens appear to boost the virus’ ability to get
inside cells. The data include outcomes in men with prostate cancer and lab studies of how androgens regulate key genes.
And preliminary observations from Spain suggest that a disproportionate number of men with male pattern baldness—which
is linked to a powerful androgen—end up in hospitals with COVID-19. Researchers are rushing to test already approved drugs
that block androgens’ effects, deploying them early in infection in hopes of slowing the virus and buying time for the immune
system to beat it back.



Trust in science is critical complying with COVID-19 prevention guidelines
Psychology, Health & Medicine: A structural equation model to identify individual characteristics that make a person
more/less likely to comply with COVID-19 prevention guidelines showed that COVID-19 risk perception and trust in science
both independently predict compliance with COVID-19 prevention guidelines, while the remaining variables in the model
(political conservatism, religious orthodoxy, conspiracy ideation and intellectual curiosity) do so via the mediating role of
trust in science.



High prevalence of venous thromboembolism (VTE) in critically ill patients with COVID-19
British Journal of Haematology: This retrospective cohort study of ICU adults with COVID-19 (N=91) found that 26.1% of
patients had VTE during their hospitalization. Elevated creatinine at time of hospital admission and hospital length of stay
were associated with a VTE diagnosis. Patient outcomes were similar for VTE and non-VTE patients in contrast to previous
reports suggesting worse outcomes amongst patients found to have VTE.



Oxford Royal College of General Practitioners clinical informatics digital hub
JMIR preprint: The paper describes the rapid design and development of the Oxford Royal College of General Practitioners
Clinical Informatics Digital (ORCHID) Hub, and its first two platforms. The Surveillance Platform will provide extended primary
care surveillance, while the Trials Platform will be a streamlined clinical trials platform integrated into routine primary care
practice. The authors applied the FAIR (Findable, Accessible, Interoperable and Reusable) metadata principles to a new,
integrated digital health hub that will extract routinely collected general practice electronic health data for use in clinical
trials and provide enhanced communicable disease surveillance. The hub will be a bottom-up, professionally led network
ensuring benefits for member practices, health service and the population served. Data will only be used for SQuIRE
(surveillance, quality improvement, research and education) purposes. There has already been a positive response from
practices and the number in the network has doubled since February 2020 to over 1,150. COVID-19 Surveillance has
delivered a trebling of virology sites to 293 (target 300), helping collect the largest ever weekly total of surveillance swabs in
the UK as well as over 3,000 SARS-CoV-2 serology samples. Practices are recruiting to the PRINCIPLE trial and follow-up of
these participants will take place through ORCHID. These initial outputs demonstrate the feasibility of ORCHID to provide an
extended national, digital health hub.

Contributing team members: Christophe G. Lambert, Shawn Stoicu, Lori Sloane, Anastasiya Nestsiarovich,
Praveen Kumar, Nicolas Lauve, Jenny Situ, Ariel Hurwitz, Morgan Edwards-Fligner, Clinton Onyango, Kristine
Tollestrup, Orrin Myers, Douglas J. Perkins.

Disclaimer: The UNM Global Health COVID-19 Briefing is provided as a public service. Sources include not only
peer-reviewed literature, but also preliminary research manuscripts that have not been peer reviewed along
with lay news media reports. The peer-review process often results in manuscript improvement, with
corrections made for errors and unsubstantiated conclusions being corrected. Furthermore, many headlines
and summaries in the briefing are written by student volunteers and others who may lack subject matter
expertise in this rapidly evolving field. As such, the headlines and summaries should not be regarded as
conclusive. Instead, readers are encouraged to use the briefing to identify areas of interest and then use the
embedded links to read and critically evaluate the primary sources.

